Sensient Technologies is scaling natural color production, and the timing is not accidental. The FDA’s FD&C phase-out deadline of December 2027 is turning supplier capacity into a competitive weapon. R&D and procurement teams should pay close attention.
TLDR
- Sensient is expanding natural color production ahead of the 2027 FDA deadline.
- Capacity constraints may become a bottleneck for late-moving CPG reformulators.
- Suppliers who scale now will control pricing and availability through 2027.
- Procurement teams face real risk if they delay sourcing conversations.
- This move signals broader supplier positioning in a tightening natural color market.
Sensient Moves Early on Natural Color Production Capacity
Sensient Technologies is ramping natural color production as U.S. regulatory pressure on synthetic dyes accelerates. Quality Assurance and Food Safety reported the scale-up as the U.S. market shifts away from FD&C synthetic dyes. Sensient is one of the largest color suppliers globally, with a natural portfolio spanning anthocyanins, carotenoids, and spirulina-based blues.
The FDA’s informal December 2027 deadline and California’s AB 2316, effective January 2028, are creating simultaneous pressure across multiple channels. Brands selling nationally cannot afford a state-by-state reformulation strategy. Speed matters now.
Why Supplier Scale Is a Reformulation Risk Factor
Natural colorants present real formulation challenges that synthetic dyes do not. pH sensitivity, heat stability, and light degradation vary significantly across source materials and application matrices. Procurement teams that wait risk both supply shortages and compressed development timelines.
Sensient’s capacity investment signals that the natural color market is entering a volume phase, not just a specialty one. Competitors including GNT, Oterra, and Chr. Hansen are similarly positioned, but early movers in capacity lock in preferred supplier status. Additionally, scale typically drives unit cost reductions that smaller natural color producers cannot match.
For R&D teams, the practical implication is clear. Sourcing conversations with major suppliers should begin now, not after formulation is complete. Capacity allocated to early reformulators will not be available to late movers in 2026 and 2027.
Source: Quality Assurance & Food Safety. URL